Spots Global Cancer Trial Database for ldk378
Every month we try and update this database with for ldk378 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) | NCT01634763 | Tumors Characte... | LDK378 | 18 Years - | Novartis | |
| A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | NCT02276027 | Adenocarcinoma ... | BYL719 INC280 LDK378 MEK162 | 18 Years - | Novartis | |
| Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT02299505 | Non-Small Cell ... | ceritinib | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | NCT02450903 | Non-Small-Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | NCT02040870 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | NCT01964157 | Non-small Cell ... | LDK378 | 20 Years - | Yonsei University | |
| A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | NCT02374489 | Cholangiocarcin... | LDK378 | 20 Years - 75 Years | National Health Research Institutes, Taiwan | |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | NCT01828112 | Non-Small Cell ... | Ceritinib pemetrexed docetaxel | 18 Years - | Novartis | |
| Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | NCT01947608 | Non-small Cell ... | LDK378 | 18 Years - | Novartis | |
| A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | NCT02374489 | Cholangiocarcin... | LDK378 | 20 Years - 75 Years | National Health Research Institutes, Taiwan | |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | NCT01828099 | Non-Small Cell ... | Ceritinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Novartis | |
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | NCT02040870 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| Managed Access Programs for LDK378, Ceritinib | NCT05100134 | Anaplastic Lymp... Non-small Cell ... | ceritinib | 12 Years - | Novartis | |
| Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | NCT01947608 | Non-small Cell ... | LDK378 | 18 Years - | Novartis | |
| Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | NCT01772797 | Anaplastic Lymp... Non-small Cell ... | LDK378 AUY922 | 18 Years - | Novartis | |
| Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) | NCT01634763 | Tumors Characte... | LDK378 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
